• Explore /
  • Poster
  • / Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3.

Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3.

Abstract Poster

Authors

null

Peter A. Fasching

Universitatsklinikum Erlangen, Erlangen, Germany

Peter A. Fasching , Guy Heinrich Maria Jerusalem , Xavier Pivot , Miguel Martin , Michele De Laurentiis , Kimberly L. Blackwell , Francisco J. Esteva , Stephen K. L. Chia , Caroline Germa , Zhongwen Tang , Shyeilla V. Dhuria , Dennis J. Slamon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—HER2/ER

Track

Breast Cancer

Sub Track

ER+

Clinical Trial Registration Number

NCT02422615

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS624)

DOI

10.1200/JCO.2016.34.15_suppl.TPS624

Abstract #

TPS624

Poster Bd #

106b

Abstract Disclosures

Similar Posters

First Author: Tomás Pascual

First Author: Fabrice Andre

First Author: Mario Campone

First Author: Binghe Xu